Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 (CYCCP) has a ROE of -23.68%, below the Healthcare sector average of 29.33%.
Get informed when a big investor buys or sells
+ Follow-23.68%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for CYCCP is -23.68%. That is below the Healthcare sector average of 29.33%. Investors often review this figure alongside Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, CYCCP currently prints -23.68% for ROE, while the sector average sits near 29.33%. That is roughly 180.7% below the sector mean. Large gaps often invite a closer look at Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's growth, margins, and balance sheet.
Return on Equity shows how effectively Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 converts resources into returns. At -23.68%, CYCCP may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting CYCCP's ROE (-23.68%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.